Overall Survival Clinical Trial
Official title:
A Retrospective Study Investigating the Combination of Irinotecan, Vincristine and Anlotinib for Epithelioid Sarcoma
Verified date | February 2023 |
Source | Peking University People's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 1, 2024 |
Est. primary completion date | October 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years and older |
Eligibility | Inclusion Criteria: - (1) Grade 2 or 3 ES confirmed histologically using the American Joint Committee on Cancer (AJCC) system ; - (2) patients presented with measurable lesions using the Response Evaluation Criteria In Solid Tumors (RECIST1.1) and were not amenable to surgical resection or radiotherapy; - (3) primary or secondary metastatic disease; - (4) received more than two courses of the VIA regimen; - (5) no concurrent treatment was given while on the VIA regimen; - (6) follow-up information and evaluation after chemotherapy were available. Exclusion Criteria: - less than 4 cycles of treatment; - medical records were not complete. |
Country | Name | City | State |
---|---|---|---|
China | Peking University People's Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate | Based on RECIST1.1 criteria, clinical evaluation was done once every 6 weeks | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04025840 -
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
|
Phase 4 | |
Completed |
NCT04111926 -
Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery
|
Phase 4 | |
Recruiting |
NCT04101760 -
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03342300 -
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
|
Phase 2/Phase 3 | |
Recruiting |
NCT03910140 -
TILA-TACE in Treatment of Hepatocellular Carcinoma
|
N/A | |
Completed |
NCT03923400 -
Jejunoileal vs Gastric GIST in the Era of Imatinib.
|
||
Withdrawn |
NCT02201381 -
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
|
Phase 3 | |
Recruiting |
NCT05392257 -
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
|
Phase 2 | |
Recruiting |
NCT05310370 -
HRD and Resistance to PAPPi in EOC Patients
|
||
Recruiting |
NCT05310357 -
Chromosomal Instability in Ovarian Cancer
|
||
Recruiting |
NCT05310305 -
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
|
||
Active, not recruiting |
NCT04245644 -
Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
|
||
Recruiting |
NCT04245410 -
Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
|
||
Completed |
NCT02980185 -
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT03967457 -
Comprehensive Study on the Quality of Life in Cervical Cancer Patients
|
||
Recruiting |
NCT04050787 -
Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer
|
N/A | |
Recruiting |
NCT03892577 -
Real-world Study for Patients With Advanced Hepatobiliary Tumors
|
||
Completed |
NCT03726021 -
Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02942238 -
Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)
|
N/A | |
Not yet recruiting |
NCT01236989 -
Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC
|
N/A |